Most solid tumors are comprised of multiple clones that ically different solid tumors implanted concurrently in NSG express orthogonal antigens, suggesting that novel strategies mice. Based on these data, we suggest that a carefully designed must be developed in order to adapt chimeric antigen receptor cocktail of bispecific adapters in combination with antifluor-(CAR) T-cell therapies to treat heterogeneous solid tumors. escein CAR T cells can overcome tumor antigen escape Here, we utilized a cocktail of low-molecular-weight bispecific mechanisms that lead to disease recurrence following many adapters, each comprised of fluorescein linked to a different CAR T-cell therapies. tumor-specific ligand, to bridge between an antifluorescein CAR on the engineered T cell and a unique antigen on the Significance: A cocktail of tumor-targeted bispecific adapters cancer cell. This formation of an immunologic synapse greatly augments CAR T-cell therapies against heterogeneous between the CAR T cell and cancer cell enabled use of a single tumors, highlighting its potential for broader applicability antifluorescein CAR T cell to eradicate a diversity of antigen-against cancers where standard CAR T-cell therapy has failed.
ASJC Scopus subject areas
- Cancer Research